They are used to determine:

Large left atrium: the test can help to determine if the left atrium is enlarged to a large blood flow then unusually
Large right atrium and ventricle: the test will help to determine if the right atrium and ventricle are enlarged due to a greater blood flow
ASD: the test will help to determine if there is a hole between the two atria and if blood is flowing through both
Stenotic mital valve: the test will help to determine if the blood flow through the mitral valve is normal or if the mitral valve is stiff, has a reduced opening, and constricting blood flow through it. Color flow mapping and Doppler imaging
A color flow and doppler imaging is used to help confirm the presence as well as evaluate the severity of ASD and MS. Chest X-ray
A chest x-ray will be given to determine the size of the heart and the blood vessels supplying blood to the lungs. Cardiac catheterization
Cardiac catheterization is done to confirm a diagnosis; it is not routinely done prior. It can also be used to evaluate the severity of ASD and measure the mitral valve area. To determine the presence ASD, a catheter is passed through the suspected hole between the atrium into the left atrium. Treatments
To treat Lutembachers syndrome, the underlying causes of the disorder must first be treated: mitral stenosis and atrial septal defect.
Pharmacology
Mechanism of action
Ferric maltol acts as a source of iron, which is essential for oxygen transport in the blood and other processes in the human body. Pharmacokinetics
The substance is a complex of iron with maltol, which is absorbed from the gut and then dissociates, releasing iron and maltol separately into the bloodstream. Iron is bound to transferrin and reaches its highest concentrations in the blood plasma one to three hours after ingestion. It is also bound to ferritin for storage. Maltol reaches its highest plasma concentrations after 1 to 1.5 hours. It is quickly metabolized to the glucuronide by UGT1A6 and eliminated via the urine with a biological half-life of 0.7 hours. 40–60% are excreted in the glucuronidized form. History
Ferric maltol was approved for medical use in the European Union in February 2016.Ferric maltol was approved for medical use in the United States in July 2019, based on evidence from three clinical trials (trial 1, trial 2, and trial 3). All 295 participants had low iron stores in the body and consequent iron deficiency anemia. In the first two trials low iron was caused by participants inflammatory bowel disease (IBD) and in the last trial, by long standing (chronic) kidney disease.Trials were conducted at 79 sites in Europe and the United States. References
External links
"Ferric maltol". Drug Information Portal. U.S. National Library of Medicine (NLM).